[go: up one dir, main page]

DE69923464D1 - Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems - Google Patents

Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems

Info

Publication number
DE69923464D1
DE69923464D1 DE69923464T DE69923464T DE69923464D1 DE 69923464 D1 DE69923464 D1 DE 69923464D1 DE 69923464 T DE69923464 T DE 69923464T DE 69923464 T DE69923464 T DE 69923464T DE 69923464 D1 DE69923464 D1 DE 69923464D1
Authority
DE
Germany
Prior art keywords
disorders
treatment
combination
nervous system
beta blockers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69923464T
Other languages
English (en)
Other versions
DE69923464T2 (de
Inventor
Klaus Wirth
Christian Englert
Helmut Bohn
Heinz Goegelein
Holger Heitsch
Uwe Gerlach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis Deutschland GmbH
Original Assignee
Aventis Pharma Deutschland GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE1998141534 external-priority patent/DE19841534A1/de
Priority claimed from DE1999101061 external-priority patent/DE19901061A1/de
Application filed by Aventis Pharma Deutschland GmbH filed Critical Aventis Pharma Deutschland GmbH
Priority to DE69923464T priority Critical patent/DE69923464T2/de
Application granted granted Critical
Publication of DE69923464D1 publication Critical patent/DE69923464D1/de
Publication of DE69923464T2 publication Critical patent/DE69923464T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C335/00Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C335/40Thioureas, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of thiourea or isothiourea groups further bound to other hetero atoms
    • C07C335/42Sulfonylthioureas; Sulfonylisothioureas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/64Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/50Compounds containing any of the groups, X being a hetero atom, Y being any atom
    • C07C311/52Y being a hetero atom
    • C07C311/54Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea
    • C07C311/57Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/58Y being a hetero atom either X or Y, but not both, being nitrogen atoms, e.g. N-sulfonylurea having sulfur atoms of the sulfonylurea groups bound to carbon atoms of six-membered aromatic rings having nitrogen atoms of the sulfonylurea groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08KUse of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00Use of organic ingredients
    • C08K5/54Silicon-containing compounds
    • C08K5/5406Silicon-containing compounds containing elements other than oxygen or nitrogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69923464T 1998-09-10 1999-09-02 Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems Expired - Lifetime DE69923464T2 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE69923464T DE69923464T2 (de) 1998-09-10 1999-09-02 Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
DE1998141534 DE19841534A1 (de) 1998-09-10 1998-09-10 Verwendung von Benzolsulfonyl(thio)harnstoffen zur Behandlung und Prophylaxe von Dysfunktionen des autonomen Nervensystems und Verwendung von Benzolsulfonyl(thio)harnstoffen in Kombination mit Betarezeptoren-Blockern
DE19841534 1998-09-10
DE1999101061 DE19901061A1 (de) 1999-01-14 1999-01-14 Verwendung von Benzolsulfonyl(thio)harnstoffen zur Behandlung von Prophylaxe von Dysfunktionen des autonomen Nervensystems und Verwendung von Benzolsulfonyl(thio)harnstoffen in Kombination mit Betarezeptoren-Blockern
DE19901061 1999-01-14
DE69923464T DE69923464T2 (de) 1998-09-10 1999-09-02 Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
PCT/EP1999/006450 WO2000015204A2 (en) 1998-09-10 1999-09-02 Use of benzenesulfonyl(thio)ureas for the treatment and prophylaxis of dysfunctions of the autonomous nervous system and use of benzenesulfonyl(thio)ureas in combination with beta-receptor blockers

Publications (2)

Publication Number Publication Date
DE69923464D1 true DE69923464D1 (de) 2005-03-03
DE69923464T2 DE69923464T2 (de) 2006-05-11

Family

ID=26048790

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69923464T Expired - Lifetime DE69923464T2 (de) 1998-09-10 1999-09-02 Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems

Country Status (27)

Country Link
US (1) US6414030B1 (de)
EP (1) EP1117409B1 (de)
JP (1) JP4733268B2 (de)
KR (1) KR100981592B1 (de)
CN (1) CN1195524C (de)
AR (1) AR020411A1 (de)
AT (1) ATE287718T1 (de)
AU (1) AU762832B2 (de)
BR (1) BR9913572A (de)
CA (1) CA2343009C (de)
CZ (1) CZ301165B6 (de)
DE (1) DE69923464T2 (de)
DK (1) DK1117409T3 (de)
ES (1) ES2235507T3 (de)
HK (1) HK1040187B (de)
HU (1) HU228988B1 (de)
ID (1) ID28854A (de)
IL (2) IL141414A0 (de)
MY (1) MY121798A (de)
NO (1) NO330215B1 (de)
NZ (1) NZ510424A (de)
PL (1) PL194986B1 (de)
PT (1) PT1117409E (de)
RU (1) RU2247562C2 (de)
TR (1) TR200100692T2 (de)
TW (1) TWI238817B (de)
WO (1) WO2000015204A2 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19917233A1 (de) * 1999-04-16 2000-10-19 Aventis Pharma Gmbh Kristalline Formen des Natriumsalzes des 5-Chlor-2-methoxy-N-(2-(4-methoxy-3-methylaminothiocarbonylaminosulfonyl-phenyl)-ethyl)- benzamids
DE19923086A1 (de) 1999-05-20 2000-11-23 Aventis Pharma Gmbh Cinnamoylaminoalkyl-substituierte Benzolsulfonamidderivate, Verfahren zu ihrer Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
US7620611B1 (en) * 1999-07-20 2009-11-17 Trilithic, Inc. Neural networks for ingress monitoring
DE10054482A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Heteroarylacryloylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10054481A1 (de) 2000-11-03 2002-05-08 Aventis Pharma Gmbh Acylaminoalkyl-substituierte Benzolsulfonamidderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE10129704A1 (de) * 2001-06-22 2003-01-02 Aventis Pharma Gmbh Verwendung von Benzolsulfonyl(thio)harnstoffen in der Behandlung des septischen Schocks
CN1330630C (zh) * 2004-03-10 2007-08-08 中国药科大学 新的磺酰(硫)脲衍生物、其制备方法及含有它们的药物组合物
DE102004061017A1 (de) 2004-12-18 2006-06-22 Sanofi-Aventis Deutschland Gmbh Piperidinsulfonylharnstoffe und -thioharnstoffe, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
KR101608702B1 (ko) * 2007-06-05 2016-04-04 사노피 디(헤테로)아릴사이클로헥산 유도체, 이들의 제조방법, 이들의 용도 및 이들을 포함하는 약제학적 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1185180B (de) * 1963-10-19 1965-01-14 Hoechst Ag Verfahren zur Herstellung von Benzolsulfonylharnstoffen
DE1518874C3 (de) * 1964-10-07 1975-03-13 Farbwerke Hoechst Ag, Vormals Meister Lucius & Bruening, 6000 Frankfurt Benzolsulfonylharnstoffe und Verfahren zu ihrer Herstellung
DE3009047A1 (de) 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Neue l-(acylamino-aryloxy-)2-hydroxy-3-alkinylaminopropane und verfahren zu ihrer herstellung
GB8716972D0 (en) * 1987-07-17 1987-08-26 Pfizer Ltd Treatment of cardiac arrhythmias
DE59401361D1 (de) 1993-02-23 1997-02-06 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe- Verfahren zu ihrer Herstellung und ihre Verwendung als Pharmazeutika
DE19505397A1 (de) * 1995-02-17 1996-08-22 Hoechst Ag Substituierte Benzolsulfonylharnstoffe und -thioharnstoffe, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
ZA961314B (en) * 1995-02-21 1996-08-27 Hoechst Ag Substituted benzenesulfonylureas and -thioreas processes for their preparation their use for the production of pharmaceutical preparations and medicaments containing them
EP0813530A1 (de) 1995-03-10 1997-12-29 Hoechst Marion Roussel, Inc. Verfahren zur herstellung von 2,3-dihydrobenzofuranol derivaten
FR2746013B1 (fr) 1996-03-18 1998-05-29 Sanofi Sa Utilisation de composes antiarythmiques dans la prevention de la mortalite post infarctus

Also Published As

Publication number Publication date
PL347215A1 (en) 2002-03-25
EP1117409A2 (de) 2001-07-25
JP2002524497A (ja) 2002-08-06
US20020082300A1 (en) 2002-06-27
CN1195524C (zh) 2005-04-06
AU5744499A (en) 2000-04-03
ES2235507T3 (es) 2005-07-01
TR200100692T2 (tr) 2001-07-23
WO2000015204A2 (en) 2000-03-23
US6414030B1 (en) 2002-07-02
DK1117409T3 (da) 2005-05-30
CZ301165B6 (cs) 2009-11-25
IL141414A0 (en) 2002-03-10
NO20011117D0 (no) 2001-03-05
NO20011117L (no) 2001-05-02
HUP0103534A2 (hu) 2002-05-29
CA2343009A1 (en) 2000-03-23
HUP0103534A3 (en) 2003-09-29
RU2247562C2 (ru) 2005-03-10
PT1117409E (pt) 2005-04-29
CN1319014A (zh) 2001-10-24
KR20010086396A (ko) 2001-09-10
DE69923464T2 (de) 2006-05-11
IL141414A (en) 2006-07-05
ATE287718T1 (de) 2005-02-15
HK1040187B (zh) 2005-09-02
PL194986B1 (pl) 2007-07-31
NO330215B1 (no) 2011-03-07
NZ510424A (en) 2003-06-30
CZ2001858A3 (en) 2001-06-13
MY121798A (en) 2006-02-28
CA2343009C (en) 2011-03-15
WO2000015204A3 (en) 2000-07-13
BR9913572A (pt) 2001-05-22
HK1040187A1 (en) 2002-05-31
TWI238817B (en) 2005-09-01
EP1117409B1 (de) 2005-01-26
AR020411A1 (es) 2002-05-08
AU762832B2 (en) 2003-07-03
KR100981592B1 (ko) 2010-09-13
HU228988B1 (hu) 2013-07-29
ID28854A (id) 2001-07-05
JP4733268B2 (ja) 2011-07-27

Similar Documents

Publication Publication Date Title
DE69925571D1 (de) Sulphonamid-derivate zur behandlung von störungen des zentralnervensystems
ATE235481T1 (de) Substituierte benzopyranderivate zur behandlung von entzündungen
DE69910368D1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
ATE224189T1 (de) Antikonvulsive sulfamatderivate zur behandlung von fettleibigkeit
NO20005864D0 (no) Quinasoler til behandling av hjernesvulst
DK1063990T3 (da) Anvendelse af Biochanin-beriget ekstrakt til behandling af östrogen-associerede lidelser
DE69737402D1 (de) Vorrichtung zur Behandlung von neurodegenerativen Störungen
DE69941566D1 (de) N-acetylhomotaurinate zur verwendung in der behandlung von hyperkinesie
IS5113A (is) Notkun antagónista CB1-viðtaka til meðhöndlunar löngunartruflana
ATA76995A (de) Stabiles präparat zur behandlung von blutgerinnungsstörungen
ATE287718T1 (de) Benzenesulfonamide derivate in kombination mit beta-blockern zur behandlung von störungen des autonomen nervensystems
ID27214A (id) Triazolopiridina untuk pengobatan gangguan trombosis
EE200000391A (et) Triasiiniühendid kesknärvisüsteemihäirete raviks
NO20012106L (no) Middel for behandling av forstyrrelser i benmetabolismen
ATE261434T1 (de) Triptolid-derivate geeignet zur behandlung von autoimmunkrankheiten
DE69735417D1 (de) 2,5-dihydroxybenzylsulfonderivate zur behandlung von sexuellen störungen
ID23175A (id) Penggunaan benzopiranol untuk mengobati gangguan syaraf
DE69726749D1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
DE60117122D1 (de) Verwendung von mirtazapin zur behandlung von schlafstörungen
ATE230741T1 (de) 3-tetrahydropyridin-4-yl-indole zur behandlung von psychotischen störungen
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
NO984189D0 (no) Fremgangsmåte for behandling av bipolar forstyrrelse

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS DEUTSCHLAND GMBH, 65929 FRANKFURT,

8364 No opposition during term of opposition